$APRE
Aprea Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023009887 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $249.7K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.699M $3.366M
YoY Change -89.13% -15.54%
% of Gross Profit
Research & Development $2.203M $1.257M
YoY Change -67.66% -69.27%
% of Gross Profit
Depreciation & Amortization $220.00 $410.00
YoY Change -94.1% -86.06%
% of Gross Profit
Operating Expenses $3.901M $4.623M
YoY Change -96.04% -42.75%
Operating Profit -$3.652M -$4.623M
YoY Change -96.29%
Interest Expense $336.2K $256.4K
YoY Change 540.53% 12909.13%
% of Operating Profit
Other Income/Expense, Net $392.6K $242.6K
YoY Change 89.6% 75.57%
Pretax Income -$3.259M -$4.380M
YoY Change -96.68% -44.81%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.259M -$4.380M
YoY Change -96.68% -44.81%
Net Earnings / Revenue -1305.26%
Basic Earnings Per Share -$0.87 -$1.34
Diluted Earnings Per Share -$0.87 -$1.34
COMMON SHARES
Basic Shares Outstanding 3.732M 3.732M
Diluted Shares Outstanding 3.732M 3.260M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.69M $31.00M
YoY Change -29.13% -34.95%
Cash & Equivalents $27.69M $31.00M
Short-Term Investments
Other Short-Term Assets $953.7K $1.023M
YoY Change -31.92% -57.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.64M $32.02M
YoY Change -29.22% -36.02%
LONG-TERM ASSETS
Property, Plant & Equipment $1.687K $1.912K
YoY Change -91.67% -90.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.18K
YoY Change 36.86%
Total Long-Term Assets $41.87K $1.912K
YoY Change -81.02% -99.35%
TOTAL ASSETS
Total Short-Term Assets $28.64M $32.02M
Total Long-Term Assets $41.87K $1.912K
Total Assets $28.68M $32.02M
YoY Change -29.5% -36.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.131M $826.0K
YoY Change -71.65% -58.45%
Accrued Expenses $2.820M $3.401M
YoY Change -23.68% -28.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.951M $4.227M
YoY Change -48.59% -37.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.951M $4.227M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.951M $4.227M
YoY Change -48.59% -37.36%
SHAREHOLDERS EQUITY
Retained Earnings -$301.4M -$298.2M
YoY Change 4.91% 57.71%
Common Stock $3.731K $3.731K
YoY Change -84.06% -83.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.42M $26.48M
YoY Change
Total Liabilities & Shareholders Equity $28.68M $32.02M
YoY Change -29.5% -36.39%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$3.259M -$4.380M
YoY Change -96.68% -44.81%
Depreciation, Depletion And Amortization $220.00 $410.00
YoY Change -94.1% -86.06%
Cash From Operating Activities -$3.217M -$2.979M
YoY Change -63.87% -45.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.140M
YoY Change
NET CHANGE
Cash From Operating Activities -3.217M -2.979M
Cash From Investing Activities
Cash From Financing Activities 0.000 5.140M
Net Change In Cash -3.217M 2.161M
YoY Change -63.87% -139.32%
FREE CASH FLOW
Cash From Operating Activities -$3.217M -$2.979M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.25
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3260484
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1095076
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001781983
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3731571
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2655269
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39069
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
463-9385
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
APRE
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3731571
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30995714
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28786647
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1022803
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1366859
CY2023Q1 us-gaap Assets Current
AssetsCurrent
32018517
CY2022Q4 us-gaap Assets Current
AssetsCurrent
30153506
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1912
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2321
CY2023Q1 us-gaap Assets
Assets
32020429
CY2022Q4 us-gaap Assets
Assets
30155827
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
826027
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
842754
CY2023Q1 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3401361
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4227388
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3201086
CY2023Q1 us-gaap Liabilities
Liabilities
4227388
CY2022Q4 us-gaap Liabilities
Liabilities
3201086
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3731571
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2655269
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3731
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2655
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335215994
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330060836
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10561452
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10623408
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298176295
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293796405
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32020429
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30155827
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1256542
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4089577
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3365961
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3985298
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4622503
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8074875
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
256410
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1971
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13797
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
136211
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
242613
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
138182
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7936693
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65505
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4317934
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8002198
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.25
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3260484
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1095076
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2084060
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65505
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7936693
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
43588826
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4379890
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-7936693
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
410
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2942
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
16244
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
2084060
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
60825
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13797
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
136211
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-344056
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1115261
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16727
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
214975
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1043029
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-840380
CY2022Q1 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-60108
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2979081
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5495329
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2160909
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5495329
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48158
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71051
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30995714
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47651774
CY2022Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
123786
CY2023Q1 us-gaap Cash
Cash
31000000.0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
610225
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
310197
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
74816
CY2023Q1 apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
101000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
60116
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
64056
CY2022Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
123786
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
389561
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75012
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1728544
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1397977
CY2023Q1 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1097765
CY2022Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
688858
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
185491
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196485
CY2023Q1 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3401361
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q1 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2020Q4 apre Universal Shelf Registration Maximum Amount To Be Issued
UniversalShelfRegistrationMaximumAmountToBeIssued
350000000.0
CY2020Q4 apre At Market Offering Program Maximum Amount To Be Issued
AtMarketOfferingProgramMaximumAmountToBeIssued
14744728
CY2020Q4 apre At Market Offering Commission Payable As Percentage Of Gross Proceeds From Sale Of Common Stock
AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock
0.03
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16244
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2100000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-23-009887-index-headers.html Edgar Link pending
0001558370-23-009887-index.html Edgar Link pending
0001558370-23-009887.txt Edgar Link pending
0001558370-23-009887-xbrl.zip Edgar Link pending
apre-20230331.xsd Edgar Link pending
apre-20230331x10q.htm Edgar Link pending
apre-20230331xex31d1.htm Edgar Link pending
apre-20230331xex31d2.htm Edgar Link pending
apre-20230331xex32d1.htm Edgar Link pending
apre-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
apre-20230331_def.xml Edgar Link unprocessable
apre-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20230331_pre.xml Edgar Link unprocessable
apre-20230331x10q_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apre-20230331_cal.xml Edgar Link unprocessable